Recent Data for PARP Inhibitors in Recurrent Ovarian Cancer
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
A detailed discussion focused on recent data on PARP inhibitors in the recurrent ovarian cancer setting.
This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value entered…
Integrating six omics datasets, Liu et al. dissect the evolutionary dynamics and spatial architecture of early-stage AM. They demonstrate that APOE+/CD163+ macrophages promote tumor EMT via…
The proteogenomic landscape in never-smoker lung cancer without known driver mutations reveals prognostic proteins and enhanced estrogen signaling that can be targeted as a potential…
Convergence Science | Cancer Research | American Association for Cancer Research .aacrcontent { display: flex; flex-direction: row; justify-content: space-between; align-items: stretch; } .intro { margin-top:…
A recent report described outcomes with the use of nivolumab plus ipilimumab as an immunotherapeutic boost in metastatic urothelial carcinoma.
According to a study published in Blood Neoplasia, standard-of-care treatment for acute myeloid leukemia is safe and effective for adults over 80.
Oncology nurses can discuss dose modifications for common smoking cessation agents with patients and providers to improve smoking cessation rates.
Sen. Richard J. Durbin (D-IL) has asked Amgen to provide copies of the company’s communications with FDA related to the dosage of Lumakras (sotorasib), a…
CMS final rule establishes prior authorization requirements, reducing burden and increasing interoperability
Results from the ORANGE II PLUS trial demonstrated that a minimally invasive, laparoscopic approach to hemihepatectomy shortened time to functional recovery compared to open, major…